GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

GSK’s Q3 2026 core earnings were $1.46 per ADS versus $1.40 expected, while revenue rose 5% at CER to $11.91 billion, slightly above the $11.80 billion consensus. Specialty Medicines sales increased 15%, led by 10% HIV and 23% oncology growth, but Vaccines sales fell 2%; the article says soft vaccine sales may have contributed to a premarket share decline. GSK maintained 2026 guidance for 3–5% revenue growth and 7–9% core operating profit and EPS growth, with EPS growth expected at the lower end of the range.

Analysis

The quarter’s key signal is mix, not the modest headline beat: specialty growth is helping replace mature-product erosion, but vaccine softness and rising R&D make the earnings bridge less clean than the operating-profit outlook suggests. The market may be treating vaccine declines as a single demand issue; distinguish temporary delivery, inventory and adjustment effects from persistent share loss. Arexvy faces a competitive RSV market, while weakness in Shingrix outside the U.S. warrants checking whether China demand normalizes or reflects a longer-term ceiling. A further deterioration in vaccine volume could also increase pricing pressure across the category.

Over the next 1–3 months, the main catalysts are vaccine sell-through and delivery normalization, plus evidence that launches and label expansion translate into sustained specialty volumes. Near term, the stock can remain headline-sensitive to vaccines; a single quarter does not establish a structural break. Over 6–18 months, HIV long-acting and newer specialty products offer mix support, but concentration in the dolutegravir franchise leaves a defined 2028–30 exclusivity risk. The £1.9bn savings target is not yet an earnings offset: execution and reinvestment needs matter, particularly with R&D rising ahead of sales. The stated 2031 ambition is not a near-term valuation floor.

Contrarian read: the vaccine miss may be over-weighted if it is mainly timing and inventory, while investors may underappreciate the quality risk in specialty growth if R&D intensity persists without pipeline conversion. Verify product-level volumes, channel inventory, launch uptake, and guidance-to-cash-flow conversion before assigning a durable premium.

Key Decisions for Investors

• Avoid chasing the initial vaccine-driven selloff; treat GSK as a watch/hold pending the next product-level vaccine update rather than assuming either a rebound or a franchise impairment.
• Consider a small, staged long only if subsequent reporting shows vaccine sell-through stabilizing and specialty growth converting into operating cash flow; define thesis failure as further broad-based vaccine volume weakness or a guidance reduction.
• Track Arexvy versus Pfizer’s RSV vaccine and Shingrix China demand separately: persistent share or demand deterioration would strengthen an underweight case, while delivery normalization without discounting would weaken it.
• Monitor R&D growth against launch uptake and the delivery of savings. If spending remains well ahead of sales without measurable pipeline or commercial progress, reassess the earnings-growth premium and the 2028–30 dolutegravir transition risk.